Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview

No Thumbnail Available

Date

2021-01-01

Authors

Matito, A.
Escribese, M. M.
Longo, N.
Mayorga, C.
Luengo-Sanchez, O.
Perez-Gordo, M.
Matheu, V
Labrador-Horrillo, M.
Pascal, M.
Seoane-Reula, M. E.

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Esmon publicidad s a, dept allergy & clin immunol, clin univ navarra
Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

The diagnosis of mast cell activation syndrome (MCAS) is defined by 3 criteria: (1) typical clinical signs and symptoms of acute, recurrent (episodic), and systemic mast cell activation (MCA); (2) increase in tryptase level to >20% + 2 ng/mL within 1-4 hours after onset of the acute crisis; and (3) response of MCA symptoms to antimediator therapy. Classification of MCAS requires highly sensitive and specific methodological approaches for the assessment of clonal bone marrow mast cells at low frequencies. The Spanish Network on Mastocytosis score has been used successfully as a predictive model for selecting MCAS candidates for bone marrow studies based on a high probability of an underlying clonal mast cell disorder. In this article, we propose a diagnostic algorithm and focus on the practical evaluation and management of patients with suspected MCAS.

Description

MeSH Terms

DeCS Terms

CIE Terms

Keywords

Anaphylaxis, &nbsp, Antimediator therapy, &nbsp, Mast cell activation syndrome, &nbsp, Mast cell mediator release-related symptoms, &nbsp, Tryptase, Indolent systemic mastocytosis, European competence network, Serum tryptase, Peripheral-blood, Venom immunotherapy, Bone-marrow, Human skin, Kit d816v, Anaphylaxis, Disorders

Citation